FAP PET/CT scans of the lungs in adults with tuberculosis
Tests [18F]-FAPI-74 PET/CT scans to look for lung scarring in tuberculosis.
Plain-language title generated from the registry record
Registry title: Fibroblast Activating Protein (FAP) PET/CT in Adults With Tuberculosis
Key facts
- Where
- Philadelphia, United StatesSee the site
- Phase
- Early phase 1
Where in United States
- Perelman School of Medicine, Nuclear MedicinePhiladelphia, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Pennsylvania
- Trial code
- NCT07830771
- Record updated
- 10 November 2026
- Original description
This is an early phase study in patients with Tuberculosis (TB) to evaluate Fibroblast Activating Protein (FAP) activation as a marker of fibrosis. The Investigators propose to use FAP PET/CT to define the extent and location of FAP signals in lungs of TB patients early in TB treatment and after TB cure. These timepoints are chosen as they could be utilized to deliver treatments designed to prevent, predict, or treat Post-transplant Lymphoproliferative Disorder (PTLD). The overarching hypothesis is that greater FAP signals in lungs of adult TB patients are associated with greater imaging manifestations of PTLD after cure.Read full original descriptionShow less
Fibroblast Activating Protein (FAP) PET/CT in Adults With Tuberculosis
This is an early phase study in patients with Tuberculosis (TB) to evaluate Fibroblast Activating Protein (FAP) activation as a marker of fibrosis. The Investigators propose to use FAP PET/CT to define the extent and location of FAP signals in lungs of TB patients early in TB treatment and after TB cure. These timepoints are chosen as they could be utilized to deliver treatments designed to prevent, predict, or treat Post-transplant Lymphoproliferative Disorder (PTLD). The overarching hypothesis is that greater FAP signals in lungs of adult TB patients are associated with greater imaging manifestations of PTLD after cure.
Inclusion: Participants will be ≥ 21 years of age; Diagnosed with microbiologically confirmed (culture or Xpert MTB/RIF PCR positive on at least one respiratory sample) pTB; Be currently on or able to initiate standard drug-sensitive pTB treatment according to IDSA guidelines; Have initiated or planning to initiate TB treatment prior to screening and enrollment; Have a Timika CXR score indicating cavitary disease; Be able and willing to provide written informed consent to participate in the study.
Exclusion: Have been administered at least 7 days of corticosteroids or any duration of another systemic investigational agent within 3 months of enrollment per medical record review or patient self-report; Any current medical condition, illness, or disorder as assessed by medical record review and/or self-reported that is considered by a physician investigator to be a condition that could compromise participant safety or successful participation in the study, including completion of the study follow-up or TB treatment; History of major alternative pulmonary disease such as asthma, chronic obstructive pulmonary disease (COPD), or interstitial lung disease as per medical record review or patient self-report. "Major" is defined as potentially resulting in pulmonary radiographic abnormalities that could interfere with interpretation of PET-CT scan data; Diagnosed with TB that is resistant to rifampin per medical record review or have only extrapulmonary TB; Women of childbearing potential may not be pregnant or breast-feeding. A negative pregnancy test will be required before [F-18]-FAPI-74 injection; Inability to tolerate imaging procedures in the opinion of an investigator or treating physician; Have symptoms or signs that, in the opinion of the investigative team, are suggestive of active TB at the time of pre-screening per patient self-report.